178 related articles for article (PubMed ID: 21077608)
1. Chemically self-assembled antibody nanorings (CSANs): design and characterization of an anti-CD3 IgM biomimetic.
Li Q; So CR; Fegan A; Cody V; Sarikaya M; Vallera DA; Wagner CR
J Am Chem Soc; 2010 Dec; 132(48):17247-57. PubMed ID: 21077608
[TBL] [Abstract][Full Text] [Related]
2. Chemically self-assembled antibody nanostructures as potential drug carriers.
Fegan A; Kumarapperuma SC; Wagner CR
Mol Pharm; 2012 Nov; 9(11):3218-27. PubMed ID: 23013206
[TBL] [Abstract][Full Text] [Related]
3. In Vivo Evaluation of Site-Specifically PEGylated Chemically Self-Assembled Protein Nanostructures.
Shah R; Petersburg J; Gangar AC; Fegan A; Wagner CR; Kumarapperuma SC
Mol Pharm; 2016 Jul; 13(7):2193-203. PubMed ID: 26985775
[TBL] [Abstract][Full Text] [Related]
4. Engineering reversible cell-cell interactions using enzymatically lipidated chemically self-assembled nanorings.
Wang Y; Kilic O; Csizmar CM; Ashok S; Hougland JL; Distefano MD; Wagner CR
Chem Sci; 2020 Oct; 12(1):331-340. PubMed ID: 34168743
[TBL] [Abstract][Full Text] [Related]
5. Eradication of Established Tumors by Chemically Self-Assembled Nanoring Labeled T Cells.
Petersburg JR; Shen J; Csizmar CM; Murphy KA; Spanier J; Gabrielse K; Griffith TS; Fife B; Wagner CR
ACS Nano; 2018 Jul; 12(7):6563-6576. PubMed ID: 29792808
[TBL] [Abstract][Full Text] [Related]
6. Targeted delivery of antisense oligonucleotides by chemically self-assembled nanostructures.
Gangar A; Fegan A; Kumarapperuma SC; Huynh P; Benyumov A; Wagner CR
Mol Pharm; 2013 Sep; 10(9):3514-8. PubMed ID: 23829765
[TBL] [Abstract][Full Text] [Related]
7. Targeted Drug Delivery by MMAE Farnesyl-Bioconjugated Multivalent Chemically Self-Assembled Nanorings Induces Potent Receptor-Dependent Immunogenic Cell Death.
Wang Y; Kilic O; Rozumalski L; Distefano MD; Wagner CR
Bioconjug Chem; 2024 May; 35(5):582-592. PubMed ID: 38701361
[TBL] [Abstract][Full Text] [Related]
8. Anti-EGFR Fibronectin Bispecific Chemically Self-Assembling Nanorings (CSANs) Induce Potent T Cell-Mediated Antitumor Responses and Downregulation of EGFR Signaling and PD-1/PD-L1 Expression.
Kilic O; Matos de Souza MR; Almotlak AA; Wang Y; Siegfried JM; Distefano MD; Wagner CR
J Med Chem; 2020 Sep; 63(18):10235-10245. PubMed ID: 32852209
[TBL] [Abstract][Full Text] [Related]
9. Prosthetic Antigen Receptors.
Shen J; Vallera DA; Wagner CR
J Am Chem Soc; 2015 Aug; 137(32):10108-11. PubMed ID: 26230248
[TBL] [Abstract][Full Text] [Related]
10. Valency of CD3 binding and internalization of the CD3 cell-surface complex control T cell responses to second signals: distinction between effects on protein kinase C, cytoplasmic free calcium, and proliferation.
Ledbetter JA; June CH; Martin PJ; Spooner CE; Hansen JA; Meier KE
J Immunol; 1986 Jun; 136(11):3945-52. PubMed ID: 3084650
[TBL] [Abstract][Full Text] [Related]
11. Human T cell activation induced by a monoclonal mouse IgG3 anti-CD3 antibody (RIV9) requires binding of the Fc part of the antibody to the monocytic 72-kDa high-affinity Fc receptor (FcRI).
Ceuppens JL; Van Vaeck F
Cell Immunol; 1989 Jan; 118(1):136-46. PubMed ID: 2521302
[TBL] [Abstract][Full Text] [Related]
12. Multivalent, Bispecific αB7-H3-αCD3 Chemically Self-Assembled Nanorings Direct Potent T Cell Responses against Medulloblastoma.
Mews EA; Beckmann P; Patchava M; Wang Y; Largaespada DA; Wagner CR
ACS Nano; 2022 Aug; 16(8):12185-12201. PubMed ID: 35876221
[TBL] [Abstract][Full Text] [Related]
13. Induction of suppressor cells to T- and B-cell proliferative responses and immunoglobulin production by monoclonal antibodies recognizing the CD3 T-cell differentiation antigen.
Kunicka JE; Platsoucas CD
Cell Immunol; 1988 Oct; 116(1):195-215. PubMed ID: 2901914
[TBL] [Abstract][Full Text] [Related]
14. In vivo administration of anti-murine CD3 monoclonal antibody induces selective, long-term anergy in CD8+ T cells.
Woodle ES; Hussein S; Bluestone JA
Transplantation; 1996 Mar; 61(5):798-803. PubMed ID: 8607186
[TBL] [Abstract][Full Text] [Related]
15. Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 x CD19 bispecific antibodies in combination with bivalent CD28 antibodies.
Bohlen H; Hopff T; Manzke O; Engert A; Kube D; Wickramanayake PD; Diehl V; Tesch H
Blood; 1993 Sep; 82(6):1803-12. PubMed ID: 7691238
[TBL] [Abstract][Full Text] [Related]
16. A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer.
Iizuka A; Nonomura C; Ashizawa T; Kondou R; Ohshima K; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Akiyama Y
Clin Cancer Res; 2019 May; 25(9):2925-2934. PubMed ID: 30737243
[TBL] [Abstract][Full Text] [Related]
17. Dichotomous effect of monocyte Fc receptor interaction on anti-CD3-induced immunoglobulin synthesis.
Wyss T; Bettens F; Walker C; Pichler WJ
Cell Immunol; 1990 Mar; 126(1):91-105. PubMed ID: 2137378
[TBL] [Abstract][Full Text] [Related]
18. Murine monoclonal IgG antibodies: differences in their IgG isotypes can affect the antibody effector activity when using human cells.
Lobo PI; Patel HC
Immunol Cell Biol; 1997 Jun; 75(3):267-74. PubMed ID: 9243292
[TBL] [Abstract][Full Text] [Related]
19. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
20. A new recombinant single chain trispecific antibody recruits T lymphocytes to kill CEA (carcinoma embryonic antigen) positive tumor cells in vitro efficiently.
Wang XB; Zhao BF; Zhao Q; Piao JH; Liu J; Lin Q; Huang HL
J Biochem; 2004 Apr; 135(4):555-65. PubMed ID: 15115782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
